Your data science team built a model that performs beautifully in a demo. Leadership is excited. The pilot generated strong early results.
And then... nothing happens.
The project stalls somewhere between "promising proof of concept" and actual production deployment.
This pattern is remarkably common in life sciences.
And contrary to what many organizations assume, the main issue is rarely the AI model itself.
The underlying risks are actually very familiar. They closely resemble the challenges the industry has already spent decades managing in computerized systems, process automation, data integrity, and validation. The difference is that AI can amplify these risks significantly faster if governance, workflows, and oversight are not designed properly from the beginning.
Four Failure Modes We See Repeatedly
1. Unclear Intended Use
Everything starts with defining what the AI system is supposed to do, for whom, and under which controls.
Without a clearly defined intended use, projects quickly become trapped in endless pilot phases. Teams struggle to align on ownership, validation expectations, risk classification, and success criteria because nobody has formally defined what "done" actually means.
This becomes especially problematic in regulated environments where governance, validation strategy, and oversight all depend on intended use.
A batch review support tool is fundamentally different from an AI system influencing product quality decisions. Without that distinction, meaningful governance conversations become impossible.
2. Weak Data Foundations
As Evelien Cools from delaware put it bluntly during our webinar: if you put bad data in, you get bad results out.
Many AI pilots succeed in controlled demo environments because the datasets are curated, simplified, or too limited to reflect operational reality. Once deployed in real-world pharmaceutical environments, these weaknesses become immediately visible.
In regulated contexts, organizations must also demonstrate:
- data provenance
- representativeness
- traceability
- bias assessment
- governance over preprocessing and labelling
Without this foundation, validation quickly collapses under audit scrutiny.
Strong AI systems are ultimately built on strong data governance, not just strong models.
3. Workflow Misalignment
One of the most underestimated barriers is operational integration.
Pharma organizations run on governed processes, documented procedures, and controlled workflows. If AI outputs are not properly embedded into standard operating procedures (SOPs), training processes, and operational decision-making, users will naturally revert to existing ways of working.
And honestly, they should.
Employees in regulated environments are trained to follow validated procedures, not experimental tooling.
This means AI adoption cannot be approached as a purely technical exercise. Workflow redesign, procedural integration, and user enablement are just as important as model performance itself.
Organizations that succeed think about AI as part of an operational system, not as an isolated technology layer.
4. Missing Controls and Monitoring
Even technically strong AI initiatives fail when governance controls are missing.
If responsibilities around monitoring, access management, retraining, incident handling, or oversight remain unclear, confidence in the system disappears quickly, both internally and externally.
The same applies to cybersecurity and intellectual property protection.
Today, an estimated 93% of AI budgets still go to technology, while only 7% goes to people. Yet in regulated environments, adoption, training, workflow redesign, and governance are often the true bottlenecks determining whether AI scales beyond pilot phase.
As Evelien explained during our webinar, many concerns around data leakage or IP exposure are not failures of AI itself. They are architectural design decisions.
Successful organizations therefore invest early in:
- secure internal environments
- controlled access structures
- monitoring frameworks
- defined ownership
- auditability
- change management processes
Without these controls, scaling AI beyond isolated pilots becomes extremely difficult.
What Successful Organizations Do Differently
Organizations that successfully move AI into production environments tend to share several common characteristics.
First, they start pragmatically.
Rather than immediately targeting high-risk GxP decision-making processes, they begin with lower-risk, high-value applications such as:
- operator support
- workflow optimization
- document review assistance
- shadow applications running alongside existing processes
This approach helps build organizational trust while generating early operational value.
Second, they integrate governance from day one.
Validation strategy, data governance, intended use, retraining criteria, and monitoring responsibilities are defined upfront rather than retrofitted later.
Human-in-the-loop oversight also plays a central role, not only because certain applications require it, but because it creates confidence and adoption across the organization.
And finally, successful organizations recognize that AI transformation is primarily a people challenge.
As Evelien highlighted during the webinar, organizations currently spend the vast majority of AI budgets on technology while significantly underinvesting in:
- training
- adoption
- workflow redesign
- change management
- organizational readiness
Yet these human factors are often the real determinants of long-term success.
Without adoption, even the strongest AI initiative remains stuck in pilot mode.
AI Adoption Requires Multidisciplinary Collaboration
Sustainable AI implementation in regulated environments requires close collaboration between:
- data scientists
- IT teams
- QA and compliance
- regulatory stakeholders
- operational business teams
And critically, these stakeholders must be involved from the ideation phase onward, not only during validation.
This is exactly where the partnership between QbD Group and delaware creates value. QbD brings compliance, validation, and regulatory expertise, while delaware contributes digital transformation, implementation, and organizational change capabilities.
Both dimensions must evolve together for AI initiatives to scale successfully.
The Bottom Line
Most AI risks can be mitigated through governance, architecture, validation, and operational design choices.
Avoiding AI altogether does not eliminate these challenges. It simply delays the learning curve while competitors continue building experience and maturity.
The organizations that solve the organizational challenge first will be the ones creating long-term competitive advantage while others remain stuck in perpetual pilot mode.
Looking to Move Beyond AI Pilot Purgatory?
Pieter Smits, Evelien Cools, and Jonathan Boel recently explored these challenges and practical solutions during a webinar on AI in Life Sciences.
Watch the on-demand session to learn how governance, validation, workflows, and organizational readiness determine whether AI initiatives scale successfully in regulated environments.
Looking to build the right foundations for compliant AI adoption? Get in touch with the QbD Group team to discuss your AI roadmap.
Watch On-Demand: AI in Life Sciences
Explore AI maturity models, governance, validation frameworks, and human-in-the-loop principles with Pieter Smits and Evelien Cools (delaware).
Watch the on-demand webinar关于作者
Division Head Software Solutions & Services at QbD Group
Jonathan co-leads the Quality Assurance and Software Solutions & Services divisions at QbD Group. He is a CSV (Computer System Validation) expert who drives digital transformation and technology-enabled compliance solutions for the life sciences industry, including QbD's cloud-based pre-validated QMS and eIFU services.
